Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects

被引：0
|
作者：
Barbara Finck
Helen Tang
Francesca Civoli
Jennifer Hodge
Hillary O’Kelly
Vladimir Vexler
机构：
[1] Coherus BioSciences,
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Biosimilar; Chemotherapy-induced febrile neutropenia; Granulocyte colony-stimulating factors; Pegfilgrastim; Pegfilgrastim-cbqv; Supportive care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：4291 / 4307
页数：16
相关论文
共 50 条
  • [31] Pharmacodynamics, safety, and immunogenicity of Pelmeg, a pegfilgrastim biosimilar in healthy subjects
    Wessels, Hendrik
    Lehnick, Dirk
    Hoefler, Josef
    Jankowsky, Ruediger
    Chamberlain, Paul
    Roth, Karsten
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (05):
  • [32] Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects
    Nakov, Roumen
    Gattu, Sreekanth
    Wang, Jessie
    Velinova, Maria
    Skerjanec, Andrej
    CANCER RESEARCH, 2018, 78 (04)
  • [33] Meta-analysis of Phase I pharmacokinetic/pharmacodynamic results of proposed biosimilar pegfilgrastim
    Nakov, R.
    Wang, J.
    Chen, Y.
    Bellon, A.
    Gattu, S.
    Krendyukov, A.
    Li, Y.
    CANCER RESEARCH, 2019, 79 (04)
  • [34] The feasibility of same day pegfilgrastim-cbqv administration in breast cancer patients receiving myelosuppressive chemotherapy regimens at a northern Virginia cancer center.
    Leiva, Maya
    Pennisi, Angela
    Harnden, Kathleen Kiernan
    Rizzo, Patricia Conrad
    Mauro, Lauren Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg, a pegfilgrastim biosimilar in healthy subjects
    Roth, Karsten
    Lehnick, Dirk
    Wessels, Hendrik
    Hoefler, Josef
    Gastl, Barbara
    Jankowsky, Ruediger
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (05):
  • [36] Pharmacokinetic-pharmacodynamic equivalence of three gliclazide formulations in healthy human male subjects
    Samad, A.
    Saha, N.
    Monif, T.
    Sharma, P. L.
    Pillai, K. K.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (07) : 444 - 450
  • [37] Meta-analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim
    Gattu, Sreekanth
    Wang, Jessie
    Bellon, Anne
    Schelcher, Celine
    Nakov, Roumen
    Arani, Ramin
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (10): : 1130 - 1141
  • [38] Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma
    McBride, Ali
    MacDonald, Karen
    Abraham, Ivo
    LEUKEMIA RESEARCH, 2021, 106
  • [39] Model-Based Approach to Selecting Pegfilgrastim Dose for Pharmacokinetic and Pharmacodynamic Similarity Studies in Biosimilar Development
    Li, Fang
    Sun, Qin
    Du, Shengnan
    Florian, Jeffry
    Wang, Yaning
    Huang, Shiew Mei
    Zineh, Issam
    Wang, Yow-Ming C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 62 - 70
  • [40] A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim
    Cornelius F. Waller
    Renger G. Tiessen
    Tracey E. Lawrence
    Andrew Shaw
    Mark Shiyao Liu
    Rajiv Sharma
    Mark Baczkowski
    Mudgal A. Kothekar
    Catherine E. Micales
    Abhijit Barve
    Gopinath M. Ranganna
    Eduardo J. Pennella
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1087 - 1095
12345